Using Metabolomics to Identify Cell Line-Independent Indicators of Growth Inhibition for Chinese Hamster Ovary Cell-based Bioprocesses.

5-hydroxyindoleacetaldehyde Chinese hamster ovary cell growth inhibitor tryptophan untargeted metabolomics

Journal

Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790

Informations de publication

Date de publication:
15 May 2020
Historique:
received: 01 04 2020
revised: 08 05 2020
accepted: 12 05 2020
entrez: 21 5 2020
pubmed: 21 5 2020
medline: 21 5 2020
Statut: epublish

Résumé

Chinese hamster ovary (CHO) cells are widely used for the production of biopharmaceuticals. Efforts to improve productivity through medium design and feeding strategy optimization have focused on preventing the depletion of essential nutrients and managing the accumulation of lactate and ammonia. In addition to ammonia and lactate, many other metabolites accumulate in CHO cell cultures, although their effects remain largely unknown. Elucidating these effects has the potential to further improve the productivity of CHO cell-based bioprocesses. This study used untargeted metabolomics to identify metabolites that accumulate in fed-batch cultures of monoclonal antibody (mAb) producing CHO cells. The metabolomics experiments profiled six cell lines that are derived from two different hosts, produce different mAbs, and exhibit different growth profiles. Comparing the cell lines' metabolite profiles at different growth stages, we found a strong negative correlation between peak viable cell density (VCD) and a tryptophan metabolite, putatively identified as 5-hydroxyindoleacetaldehyde (5-HIAAld). Amino acid supplementation experiments showed strong growth inhibition of all cell lines by excess tryptophan, which correlated with the accumulation of 5-HIAAld in the culture medium. Prospectively, the approach presented in this study could be used to identify cell line- and host-independent metabolite markers for clone selection and bioprocess development.

Identifiants

pubmed: 32429145
pii: metabo10050199
doi: 10.3390/metabo10050199
pmc: PMC7281457
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIH HHS
ID : CA211839-01
Pays : United States
Organisme : Biogen
ID : n/a

Déclaration de conflit d'intérêts

The authors declare no conflict of interest. R.R., K.M., R.K., and A.G. were employees of Biogen at the time the study was performed. J.L. is currently an employee of Biogen. Only the authors were involved in the study. As a company, Biogen had no role in composing the manuscript. 

Références

BMC Genomics. 2006 Jun 08;7:142
pubmed: 16762068
Nat Biotechnol. 2004 Nov;22(11):1393-8
pubmed: 15529164
Rapid Commun Mass Spectrom. 2009 Dec;23(23):3763-71
pubmed: 19902412
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):263-9
pubmed: 22436749
Cell Syst. 2016 Nov 23;3(5):434-443.e8
pubmed: 27883890
Metab Eng. 2019 Jan;51:9-19
pubmed: 30227251
Nucleic Acids Res. 2013 Jan;41(Database issue):D801-7
pubmed: 23161693
Biotechnol Bioeng. 2012 Jun;109(6):1404-14
pubmed: 22407794
J Cheminform. 2016 Jan 29;8:3
pubmed: 26834843
Int J Cancer. 2015 Feb 1;136(3):516-26
pubmed: 24895217
Biotechnol Prog. 2013 Nov-Dec;29(6):1519-27
pubmed: 23926083
Nat Rev Mol Cell Biol. 2016 Jul;17(7):451-9
pubmed: 26979502
Anal Chem. 2014 Jul 1;86(13):6393-400
pubmed: 24896981
Biotechnol J. 2018 Mar;13(3):e1700227
pubmed: 29072373
Nat Biotechnol. 2012 Sep;30(9):826-8
pubmed: 22965049
Biotechnol Bioeng. 2011 Dec;108(12):3025-31
pubmed: 21769861
Hepatology. 2010 Apr;51(4):1244-54
pubmed: 20099302
Anal Chem. 2017 Dec 19;89(24):13097-13104
pubmed: 29156137
Biotechnol Prog. 2017 Nov;33(6):1468-1475
pubmed: 28842948
Biotechnol Bioeng. 2017 Aug;114(8):1779-1790
pubmed: 28409820
Nat Rev Neurosci. 2006 Apr;7(4):295-309
pubmed: 16552415
Anal Chem. 2012 Jan 3;84(1):283-9
pubmed: 22111785
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W94-9
pubmed: 24895432
Nucleic Acids Res. 2016 Jan 4;44(D1):D515-22
pubmed: 26476456
Biotechnol J. 2018 Mar;13(3):e1700499
pubmed: 29393587
Genome Biol. 2003;4(10):R70
pubmed: 14519205
Biotechnol Bioeng. 2011 Jun;108(6):1328-37
pubmed: 21328318
Cytotechnology. 2013 Aug;65(4):577-86
pubmed: 23179090
Nat Biotechnol. 2014 Oct;32(10):992-1000
pubmed: 25299917
Biotechnol Bioeng. 2012 Jun;109(6):1415-29
pubmed: 22252269
Biotechnol Bioeng. 2017 May;114(5):1006-1015
pubmed: 27943242
Biotechnol Prog. 2010 Sep-Oct;26(5):1400-10
pubmed: 20945494
Bioinformatics. 2010 Oct 1;26(19):2488-9
pubmed: 20671148
Bioinformatics. 2018 Dec 15;34(24):4313-4314
pubmed: 29955821
Metabolomics. 2018 Jul 9;14(7):98
pubmed: 30830409
Trends Biotechnol. 2010 Sep;28(9):476-84
pubmed: 20691487
J Biotechnol. 2011 Jan 20;151(2):218-24
pubmed: 21167884
BMC Genomics. 2008 Mar 20;9:134
pubmed: 18366702
Biotechnol Bioeng. 2012 Dec;109(12):3103-11
pubmed: 22711553

Auteurs

Nicholas Alden (N)

Department of Chemical and Biological Engineering, Tufts University, 4 Colby Street, Medford, MA 02155, USA.

Ravali Raju (R)

Biogen, 225 Binney St, Cambridge, MA 02142, USA.

Kyle McElearney (K)

Biogen, 225 Binney St, Cambridge, MA 02142, USA.

James Lambropoulos (J)

Biogen, 225 Binney St, Cambridge, MA 02142, USA.

Rashmi Kshirsagar (R)

Biogen, 225 Binney St, Cambridge, MA 02142, USA.

Alan Gilbert (A)

Biogen, 225 Binney St, Cambridge, MA 02142, USA.

Kyongbum Lee (K)

Department of Chemical and Biological Engineering, Tufts University, 4 Colby Street, Medford, MA 02155, USA.

Classifications MeSH